Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorBURGUET, Laure
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDUVIGNAUD, Alexandre
dc.contributor.authorNGUYEN, Duc
dc.contributor.authorRECEVEUR, Marie-Catherine
hal.structure.identifierImmunology from Concept and Experiments to Translation [ImmunoConcept]
dc.contributor.authorKAMINSKI, Hannah
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPELLEGRIN, Isabelle
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorROGUES, Anne-Marie
dc.contributor.authorPEUCHANT, Olivia
dc.contributor.authorMOREAU, Karine
hal.structure.identifierImmunology from Concept and Experiments to Translation [ImmunoConcept]
dc.contributor.authorMERVILLE, Pierre
hal.structure.identifierImmunology from Concept and Experiments to Translation [ImmunoConcept]
dc.contributor.authorCOUZI, Lionel
dc.date.accessioned2021-07-05T09:29:23Z
dc.date.available2021-07-05T09:29:23Z
dc.date.issued2022-04
dc.identifier.issn1201-9712en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/94969
dc.description.abstractEnOBJECTIVES: To describe the investigation, follow-up, management and outcomes in a cohort of chronic kidney disease and kidney transplant recipients exposed to a case of pulmonary tuberculosis. METHODS: Contacts were investigated following a concentric circles approach and followed-up according to their level of priority. In those with an evidence of latent tuberculous infection, treatment decision was based on the level of exposure, individual vulnerability, as well as the results of an interferon-gamma release assay. RESULTS: 130 patients with chronic kidney disease and 180 kidney transplant recipients were identified as contacts and followed-up over a two-year period.Only few vulnerable high-priority contacts received an anti-tuberculosis treatment, including the 2 (100%)highly exposed patients in circle 1, 11/78(14.1%)chronic kidney disease patients and 4/142 (2.8%) kidney transplant recipients in circle 2, and10/52 (19.2%) chronic kidney disease patients and 2/36 (5.6%) kidney transplant recipients in circle 3;all having a positive interferon-gamma release assay result. No incident case of tuberculosis disease occurred. CONCLUSIONS: These findings suggest that latent tuberculosis treatment, as recommended in European guidelines, might be reasonably avoided in vulnerable high-priority contacts of circle 2 with a negative interferon-gamma release assay in countries with low prevalence of tuberculosis.
dc.language.isoENen_US
dc.subject.enContacts
dc.subject.enTuberculosis
dc.subject.enInterferon Gamma Release Assay
dc.subject.enTherapy
dc.subject.enProphylaxis
dc.title.enPulmonary Tuberculosis and Management of Contact Patients in a Department of Nephrology and Kidney Transplantation
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.ijid.2021.05.045en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34029706en_US
bordeaux.journalInternational Journal of Infectious Diseasesen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamIDLICen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.teamAHEAD_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressouien_US
hal.identifierhal-03277960
hal.version1
hal.date.transferred2021-07-05T09:29:28Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Infectious%20Diseases&rft.date=2022-04&rft.eissn=1201-9712&rft.issn=1201-9712&rft.au=BURGUET,%20Laure&DUVIGNAUD,%20Alexandre&NGUYEN,%20Duc&RECEVEUR,%20Marie-Catherine&KAMINSKI,%20Hannah&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée